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ABSTRACT 509 
Intracranial volume reflects the maximally attained brain size during development, and remains 510 
stable with loss of tissue in late life. It is highly heritable, but the underlying genes remain 511 
largely undetermined. In a genome-wide association study of 32,438 adults, we discovered five 512 
novel loci for intracranial volume and confirmed two known signals. Four of the loci are also 513 
associated with adult human stature, but these remained associated with intracranial volume 514 
after adjusting for height. We found a high genetic correlation with child head circumference 515 
(ρgenetic=0.748), which indicated a similar genetic background and allowed for the identification 516 
of four additional loci through meta-analysis (Ncombined = 37,345). Variants for intracranial 517 
volume were also related to childhood and adult cognitive function, Parkinson’s disease, and 518 
enriched near genes involved in growth pathways including PI3K-AKT signaling. These 519 
findings identify biological underpinnings of intracranial volume and provide genetic support 520 
for theories on brain reserve and brain overgrowth. 521 
The intricate genetic control of the human brain, complemented by environmental factors, leads to the 522 
observed variations in brain size in human populations1. Intracranial volume is closely related to brain 523 
volume in early life as the brain grows.2,3 However, it becomes stable after the brain has fully 524 
developed and remains unaffected by later age-related changes such as brain atrophy4,5, thus 525 
representing the maximal attained brain size. Discovering genetic variants that influence intracranial 526 
volume can contribute to our understanding of brain development and related diseases, but prior 527 
studies have only identified two influential genetic loci6-9.  528 
Here, we performed genome-wide association studies in populations from the Cohorts for Heart and 529 
Aging Research in Genomic Epidemiology (CHARGE)10 and Enhancing NeuroImaging Genetics 530 
through Meta-Analysis (ENIGMA)11 consortia on intracranial volume measured by magnetic 531 
resonance imaging. Genotypes were imputed to the 1000 Genomes reference panel (phase 1, version 532 
3). Meta-analysis revealed five novel loci associated with intracranial volume. We also discovered 533 
genome-wide overlap between intracranial volume and other key traits including height, cognitive 534 
ability, and Parkinson’s disease. Furthermore, we found relatively enriched patterns of association for 535 
certain functional categories of variants and near genes that are involved in specific pathways.   536 
RESULTS 537 
Genome-wide association studies 538 
Detailed information on the population characteristics, image acquisition and processing, and genetic 539 
quality control can be found in the Online Methods and Supplementary Tables S1-3. 540 
The discovery meta-analysis (N = 26,577) yielded seven genome-wide significant (p < 5 x 10-8) loci, 541 
five of them novel (Figures 1-2; Table 1). The quantile-quantile plot showed inflation (λ = 1.092; 542 
Supplementary Figure S1), which we determined to be mainly due to polygenicity rather than 543 
cryptic relatedness or population stratification using LD score regression12. Next we analyzed 544 
European samples (N = 2,362; not included in the discovery sample) and generalization samples with 545 
African (N = 938), Asian (N = 955), and Hispanic (N = 1,605) ancestries (Table 1). All variants had 546 
the same direction of effect in the additional European samples (sign test, P = 0.0078), and three 547 
variants replicated, at nominal significance. Although sample sizes were generally small for the non-548 
Europeans, here too, the direction of effect was generally concordant with the discovery (sign test, P = 549 
0.039). Five nominally significant associations were detected across all three ethnicities.  550 
Next we were able to map the association to novel variants for two previously identified loci at 551 
chromosome 17q21 (rs199525; P = 3.8 x 10-21) and 6q22 (rs11759026; P = 2.2 x 10-20)6,7. The five 552 
novel loci were on chr 6q21 (rs2022464; P = 3.7 x 10-11), chr 10q24 (rs11191683; P = 1.1 x 10-10), chr 553 
3q28 (rs9811910; P = 2.0 x 10-9), chr 12q14 (rs138074335/ rs7312464; P = 6.2 x 10-9), and chr 12q23 554 
(rs2195243; P = 1.5 x 10-8). Functional annotation of the variants and those in LD (r2 >0.8) can be 555 
found in Supplementary Table S4. 556 
Height-adjusted analyses 557 
Four of the seven loci for intracranial volume were previously discovered for height (17q21, 6q22, 558 
6q21, and 12q14), prompting us to investigate genome-wide overlap between the two traits. As height 559 
and intracranial volume are correlated (weighted average Pearson’s r = 0.556; Supplementary Table 560 
S5) and this could drive association signals, we performed a GWAS of intracranial volume adjusted 561 
for height in the studies that had measured height (N = 21,875). Findings were compared to the 562 
corresponding subset of studies without adjustment (N = 22,378). Using LD score regression (Online 563 
Methods), we found that there is considerable genetic correlation between intracranial volume and 564 
height (ρgenetic = 0.241, P = 2.4 x 10-10), which disappears after adjusting for height (ρgenetic = 0.049, P = 565 
0.21) (Table 2). The associations of the seven intracranial volume loci, however, remained significant 566 
after adjusting for height (Supplementary Table S6). To investigate whether more height loci were 567 
associated with intracranial volume independently of height, we analyzed all 697 genome-wide 568 
significant height variants13. An additional 73 variants (10.7%; 14 variants not available) showed 569 
nominally significant associations with intracranial volume but were not attenuated after adjustment 570 
for height, although none survived Bonferroni correction (Supplementary Table S7). For some 571 
variants, the direction of effect was discordant, i.e. positive for height and negative for intracranial 572 
volume. Furthermore, a polygenic score of the 697 variants predicted intracranial volume, and this 573 
was also the case after adjustment for height in a subset of the studies (Supplementary Table S8).  574 
Genetic correlation 575 
In addition to height, we examined the genome-wide genetic overlap between intracranial volume and 576 
other anthropometric traits, cognitive function, and neurodegenerative diseases (Table 2). We found a 577 
strong genetic correlation with child head circumference (ρgenetic = 0.748), which validates intracranial 578 
volume as a measure of brain growth during early development. Since this high correlation indicates 579 
that the genetic determinants of intracranial volume and child head circumference are largely shared, 580 
we aimed to leverage this information by performing a meta-analysis of both traits. The meta-analysis 581 
(combined N = 37,345) led to the identification of four novel loci (Figure 3; Supplementary Table 582 
S9). 583 
Weaker correlations were found with birth length and weight (ρgenetic < 0.3), which attenuated after 584 
adjusting for height. Additionally, intracranial volume was genetically correlated with cognitive 585 
function in childhood (ρgenetic = 0.277, P = 2.2x10-3) as well as general cognitive function in middle-586 
aged and older adults (ρgenetic = 0.202, P = 6.3x10-4). Furthermore, we found a positive genetic 587 
correlation with Parkinson’s disease (ρgenetic = 0.315, P = 6.6 x 10-7), but there was no significant 588 
genetic overlap with Alzheimer’s disease, white matter lesions, and psychiatric traits. 589 
Enrichment analyses 590 
Next, we assessed whether particular subsets of genetic variants were enriched for association with 591 
intracranial volume using partitioned heritability and pathway analyses (Online Methods). Overall, 592 
we found that common variants genotyped from across the whole genome explained 25.42% (S.E. 593 
2.73%) of the variation in intracranial volume. Partitioning heritability by chromosome showed that 594 
chromosome 22 contributed twofold more to variation in intracranial volume than would be expected 595 
by its size (Figure 4A), which was not seen for any of the other complex traits from the genetic 596 
correlation analysis (Supplementary Figure S2). Partitioning by functional elements showed an 597 
enrichment for introns and several histone codes that are found in actively transcribed promoters 598 
(Figure 4B). The enrichment for intronic variants was specific to intracranial volume, whereas the 599 
other functional classes were also enriched in other complex traits (Supplementary Figure S3).  We 600 
also found that loci associated with intracranial volume cluster around genes involved in specific 601 
pathways, with 94 pathways significantly enriched (Figure 4C; full list in Supplementary Table 602 
S10). These pathways included all cell cycle components – the M-, G1-, S-, and G2-phases – and 603 
various growth factor signaling pathways, including PI3K-AKT. 604 
Head growth trajectories 605 
Although intracranial volume reflects brain development until maturation, and we identified 606 
influences of many growth-related processes contributing to its variation, all loci were still discovered 607 
via cross-sectional associations in adults. Therefore, we tested whether a polygenic score of the 7 loci 608 
could predict head growth in a longitudinal cohort of 2,824 children of European ancestry followed 609 
prenatally until 6 years of age (Online Methods). We found that a higher polygenic score, 610 
representing a genetically larger intracranial volume in adults, was also associated with a larger child 611 
head circumference (β = .031 per SD, P = 0.010). Furthermore, the effect of the polygenic score was 612 
age-dependent and more prominent in older children (β = 0.0080 per SD polygenic score per year age, 613 
Pinteraction = 0.0091). When investigating the individual loci separately, both 17q21 and 12q14 showed 614 
significant associations with child head circumference, but they influenced the trajectories of head 615 
growth differently (Figure 4A-B). For 17q21, the negative impact of the G allele on head 616 
circumference becomes apparent postnatally and increases towards six years, whereas the 12q14 locus 617 
exerts an effect from early pregnancy to one year of age, but is less prominent later in life.  618 
DISCUSSION 619 
Genes contributing to variation in the size of the human brain remain challenging to discover. In a 620 
worldwide project of unprecedented scale, we performed the largest-ever meta-analysis of genome-621 
wide association studies of intracranial volume. We discovered five novel genetic loci associated with 622 
intracranial volume, and replicated two known signals. The discovery sample included Europeans 623 
only, but the direction of effect was similar in other ethnicities. The genes in these loci provide 624 
intriguing links between maximal brain size and various processes, including neural stem cell 625 
proliferation (FOXO3), neurodegeneration (MAPT), bone mineralization (CENPW), growth signaling 626 
(IGF1, HMGA2), DNA replication (GMNC), and rRNA maturation (PDCD). On a genome-wide 627 
scale, we discovered evidence of genetic correlation between intracranial volume and other key traits 628 
such as height and cognitive function, and also with Parkinson’s disease, indicating that the genes 629 
underlying brain development have far-reaching effects well beyond the initial years of life.  630 
The 17q21 locus tags a 1Mb inversion that is under positive selection in Caucasians14. It contains 631 
multiple genes including the MAPT and KANSL1. The MAPT gene is consistently implicated in 632 
various neurodegenerative disorders including Parkinson’s disease, Alzheimer’s disease, and 633 
frontotemporal dementia15,16, and microduplications have been reported to cause microcephaly17. 634 
KANSL1 causes the reciprocal 17q21.31 microdeletion syndrome - a multisystem disorder with 635 
intellectual disability, hypotonia and distinctive facial features18. The signal at 6q22 is intergenic to 636 
CENPW and RSPO3, but now lies 172kb closer to CENPW. Interestingly, multiple variants at this 637 
locus independently influence bone mineral density19,20, and our signal particularly overlaps with the 638 
variant showing high specificity for the skull20. 639 
The significant variants at chr 6q21 span FOXO3, a gene associated with longevity21, height13, and 640 
serum IGF1 levels22. FOXO3 regulates the proliferation of neural stem cells, and knockout mice show 641 
larger brains resulting from increased proliferation immediately after birth23, followed by a decrease 642 
in adult neural stem cell renewal23,24. The rs3800229 variant in strong LD with our top variant (r2 = 643 
0.84) contains chromatin promoter marks in the fetal brain (Supplementary Table S4), and regulates 644 
serum IGF1 levels in infants25. This provides a link to the genome-wide significant locus on chr12q23 645 
near IGF1, pointing to a potential mechanism through which these loci may affect brain growth. 646 
Chr12q23 lies 20Mb from one of two loci previously detected for head circumference in children26, 647 
but that region was not associated with intracranial volume in our study (rs7980687; P = 0.06). The 648 
other reported child head circumference locus, however, corresponded to our chr12q14 signal, with 649 
the top variant lying 14kb downstream of HMGA2, and already showed suggestive association with 650 
intracranial volume in a previous report7. It has also previously been associated with height13 and is 651 
essential for growth27. The chr10q24 LD-block covers multiple genes, but an intronic variant within 652 
PDCD11 is most significant. PDCD11 encodes an NF-kappa-B-binding protein required for rRNA 653 
maturation and generation of 18S rRNA28. A variant in LD (rs7894407) has recently been identified in 654 
a GWAS of cerebral white matter hyperintensities29. The top chr3q28 variant is located upstream of 655 
GMNC, which codes for the geminin coiled-coil domain-containing protein essential for DNA 656 
replication30. 657 
Prior efforts to identify variants affecting intracranial volume were much smaller and critically did not 658 
adjust for height6-9. We found that 4 out of 7 loci were already discovered for height13, but also that 659 
over 10% of the known ‘height loci’ actually affect intracranial volume, even after regressing out 660 
height. Interestingly, some variants showed discordant associations for height and intracranial volume 661 
- in line with the recent finding that different height loci disproportionally affect either leg length or 662 
spine/head length31 and may be a marker for pathological development32.  Also, height might thus 663 
serve as a proxy phenotype for intracranial volume, with the tenfold larger sample of the height 664 
GWAS giving greater power to detect associations. Neural genes are also enriched in pathway 665 
analyses of height13. However, to fully disentangle whether these identified genes are ‘height genes’, 666 
‘brain volume genes’, or ‘growth genes’ (i.e., pleiotropic), a large collaborative effort is needed that 667 
examines the association of these variants with both intracranial volume and height under various 668 
models. 669 
When investigating genome-wide overlap with other traits, we found a strong correlation with child 670 
head circumference, underlining that intracranial volume is valid measure for maximal attained brain 671 
size. We were able to leverage this genetic link by meta-analyzing both traits, which led to the 672 
identification of four additional loci (2q32.1, 3q23, 7p14.3, 22q13.2). The correlations with birth 673 
length and weight were weaker and decreased further after adjusting for height, so a similar 674 
phenotypic correlation between head size and body size at younger age may drive these correlations. 675 
Intracranial volume was also genetically associated with cognitive function in childhood as well as 676 
general cognitive function in middle-aged and older individuals. This indicates that variation in 677 
maximally attained brain size during development shares a genetic basis with cognitive ability later in 678 
life and supports intracranial volume as a measure of brain reserve5.  679 
The brain reserve hypothesis states that premorbid brain size can modify resilience to age-related 680 
brain pathology33, but there was no indication of a genome-wide overlap with Alzheimer’s disease. 681 
However, we found a positive genetic correlation with Parkinson’s disease that rather points to a brain 682 
“overgrowth” hypothesis. Interestingly, the IGF1 and the PI3K-AKT pathways, key factors in both 683 
growth signaling and our current study of intracranial volume, are neuroprotective in a model system 684 
of Parkinson’s disease34. There were no correlations with other neurological or psychiatric traits, 685 
indicating that this finding might be specific to Parkinson’s disease. However, it is important to note 686 
that there is a certain extent of variation in the sample size and power of these studies, and larger 687 
GWAS might reveal genetic correlation with other traits as well. 688 
It is not yet known if variance in intracranial volume, within the normal range, contributes to disease 689 
risk or brain reserve. There is no doubt that in the pathological extremes of the distribution, size can 690 
matter, as in disorders such as microcephaly or macrocephaly. Here we found evidence for a shared 691 
genetic background between intracranial volume and cognitive function, and risk of Parkinson’s 692 
disease. While not definitive, these are novel pieces of empirical evidence in the debate on whether or 693 
not whole brain size matters. 694 
The pathway analyses highlight cellular growth and proliferation and included all components of the 695 
cell cycle (M-, G1-, S-, and G2-phase) and various growth factor signaling pathways. PI3K-AKT 696 
signaling has a well described role in brain overgrowth disorders35,36, and was the only significant 697 
pathway using a different pathway analysis method (Supplementary Table S11). Interestingly, AKT3 698 
intronic variants showed suggestive evidence for association with intracranial volume (rs7538011; P = 699 
9.2 x 10-7). Deletions of AKT3 cause microcephaly syndromes37, whereas duplications give rise to 700 
macrocephaly38. Similar to FOXO3, it is part of the IGF1 signaling pathway, which is important for 701 
human longevity39. The PI3K-AKT signaling pathway seems to have an important role in brain 702 
growth, not only in pathological extremes, but also for normal variation at a population level. Other 703 
pathways enriched for association with intracranial volume highlight neuronal functions such as 704 
neurotransmission and axon guidance. 705 
We identified novel loci all influencing intracranial volume and, at a genome-wide level, there seem 706 
to be common pathways, but our longitudinal study reveals that their developmental effects are 707 
complex. The loci influenced trajectories of head growth differently; it also would be interesting to 708 
investigate whether their spatial profiles of effects are distinct, where certain loci promote growth of 709 
particular brain regions. 710 
Here we identified key genetic loci implicated in intracranial volume within a global collaborative 711 
effort, followed by computational analyses to determine the important biological pathways and 712 
functional elements. While the majority of the genetic variants are yet to be discovered, it is clear that 713 
these will provide better insight into brain development, but also into related neuropsychiatric traits 714 
such as cognitive functioning and even for neurodegeneration late in life. Uncovering the remaining 715 
heritability will advance our understanding of the brain’s complex genetic architecture. 716 
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1212 
FIGURE LEGENDS 1213 
Figure 1. Common genetic variants associated with intracranial volume. 1214 
Manhattan plot where every point represents a single genetic variant plotted according to its genomic 1215 
position (x-axis) and its –log10(p-value) for association with intracranial volume (y-axis). Variants in 1216 
blue are genome-wide significant in a previously known locus, whereas red variants reach genome-1217 
wide significant for the first time in that locus. The dashed horizontal line represents a significance 1218 
threshold of p-value < 10-6 and the full horizontal line represents genome-wide significance of p-value 1219 
< 5 x 10-8. Variants surpassing these thresholds are indicated by larger points. 1220 
Figure 2. Regional association and functional annotation of novel genome-wide significant loci. 1221 
Regional association plots for the five novel genome-wide significant loci of intracranial volume with 1222 
gene models below (GENCODE version 19). Annotation tracks below from the Roadmap 1223 
Epigenomics Consortium57 highlight the genomic region that likely harbors the causal variant(s) (r2 > 1224 
0.8 from the top SNP). See Online Methods for detailed track information. Plots were generated 1225 
using the LocusTrack software (http://gump.qimr.edu.au/general/gabrieC/LocusTrack/). 1226 
Figure 3. Meta-analysis of intracranial volume and child head circumference. 1227 
A ‘twin’ Manhattan plot shows every variant twice: once for the discovery analysis and once for the 1228 
combined discovery plus replication analysis. The least significant association of the variant-pair is 1229 
plotted in grey (alternating light and dark between chromosomes). The most significant association of 1230 
the variant-pair is plotted in red if is from the combined analysis (i.e., the association became more 1231 
significant after meta-analyzing with the child head circumference GWAS) and in turquoise if it is 1232 
from the discovery analysis (i.e., the association became less significant after meta-analyzing with the 1233 
child head circumference GWAS). The dashed horizontal line represents a significance threshold of p-1234 
value < 10-6 and the full horizontal line represents genome-wide significance of p-value < 5 x 10-8. 1235 
Variants surpassing these thresholds are indicated by larger and brighter points. 1236 
Figure 4. Enrichment analyses of common variants associated with intracranial volume. 1237 
Enrichment of subsets of variants for association with intracranial volume: A) by chromosomes, B) by 1238 
functional subtype, and C) by pathway. See Online Methods for additional information. 1239 
Figure 5. Temporal trends of intracranial volume loci during pre- and postnatal brain 1240 
development. 1241 
Mean predicted values of standardized head circumference using linear mixed models with age, sex, 1242 
and the rs199525 or rs138074335 variants. The blue line represents children not carrying the risk 1243 
allele, purple only a single risk allele, and red with two risk alleles. See Online Methods for 1244 
additional information. Total sample size is 2,824. 1245 
TABLES 1246 
Table 1. Association of genome-wide significant loci for intracranial volume in European, African, Asian, and Hispanic populations. 1247 
      
European 
discovery  
(N=26,577)
European 
replication  
(N=2,363) 
African 
generalization 
(N=938)
Asian 
generalization
(N=955) 
Hispanic 
generalization
(N=1605) 
Genetic variant Locus Position A1 A2 Freq β P β P β P β P β P 
                
rs199525 17q21 44847834 T G 0.80 .102 3.8x10-21 .024 0.407 .358 1.3x10-3 .264 0.406 .035 0.493 
rs11759026 6q22 126792095 A G 0.76 -.095 2.2x10-20 -.019 0.528 -.131 0.194 -.071 0.123 -.046 0.209 
rs2022464 6q21 108945370 A C 0.30 -.063 3.7x10-11 -.090 4.7x10-3 -.060 0.233 -.105 0.035 -.088 0.013 
rs11191683 10q24 105170649 T G 0.33 .059 1.1x10-10 .040 0.174 .187 0.021 .085 0.075 -.005 0.911 
rs9811910 3q28 190670902 C G 0.08 .096 1.2x10-9 .075 0.010 .346 0.020 .101 0.621 -.148 0.187 
rs138074335 12q14 66374247 A G 0.59 .051 6.2x10-9 .106 2.9x10-4 -.016 0.735 -.004 0.951 .001 0.984 
rs2195243 12q23 102922986 C G 0.22 -.059 1.5x10-8 -.044 0.132 .037 0.585 -.020 0.774 -.093 0.101 
 1248 
Abbreviations: A1 = effect allele, A2 = reference allele, Freq = frequency of the effect allele, SE = standard error, N = sample size. 1249 
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 1255 
Table 2. Genetic correlation between intracranial volume and other anthropometric traits, cognitive function, and neurodegenerative diseases. 1256 
   Intracranial volume 
Full sample (N=26,577)
Intracranial volume 
Height subset (N=22,378)
Intracranial volume 
Height adjusted (N=21,875) 
Phenotype N total N cases ρgenetic SE P ρgenetic SE P ρgenetic SE P 
            
Anthropometric traits            
Adult height 253,280 - .249 .037 1.4x10-11 .241 .038 2.4x10-10 .049 .039 0.21 
Child head circumference 10,768 - .748 .121 5.5x10-10 .758 .124 1.1x10-9 .750 .126 2.5x10-9 
Birth length 28,459 - .296 .087 6.7x10-4 .278 .087 1.3x10-3 .192 .088 0.029 
Birth weight 26,836 - .285 .081 4.4x10-4 .219 .082 7.9x10-3 .160 .086 0.062 
Neurological traits            
Childhood cognitive function 12,441 - .277 .090 2.2x10-3 .277 .091 2.5x10-3 .257 .090 4.2x10-3 
Adult cognitive function 53,949 - .202 .059 6.3x10-4 .205 .060 6.0x10-4 .198 .059 6.9x10-4 
Alzheimer's Disease 54,162 17,008 -.070 .097 0.47 -.049 .097 0.61 -.043 .098 0.66 
Parkinson's Disease 108,990 13,708 .315 .063 6.6x10-7 .316 .070 5.5x10-6 .335 .072 3.0x10-6 
White matter lesions 17,936 - .112 .075 0.13 .111 .078 0.16 .096 .079 0.23 
Psychiatric traits            
Autism 10,263 4,949 -.011 .069 0.87 -.036 .074 0.63 .026 .071 0.72 
Bipolar disorder 11,810 6,990 .070 .071 0.33 .007 .075 0.93 -.004 .076 0.95 
Major depressive disorder 16,610 9,227 .002 .100 0.98 .025 .098 0.80 .005 .096 0.96 
Schizophrenia 17,115 9,379 .054 .056 0.33 .017 .058 0.77 -.009 .058 0.87 
Extraversion 63,030 - -.041 .092 0.65 -.101 .095 0.29 -.097 .092 0.29 
Neuroticism 63,661 - -.017 .109 0.87 .035 .106 0.74 .070 .111 0.53 
 1257 
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Genetic correlation between various phenotypes and intracranial volume in the complete discovery sample (“Full sample”), adjusted for height in 1258 
the studies that had measured height (“Height adjusted”), and the corresponding subset of studies without adjustment (“Height subset”).  1259 
Abbreviations: SE = standard error. 1260 
 1261 
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 1262 
ONLINE METHODS 1263 
Study population 1264 
This study reports data on 32,438 subjects from 52 study sites that are part of the Cohorts for Heart 1265 
and Aging Research in Genomic Epidemiology (CHARGE)10 consortium and Enhancing 1266 
NeuroImaging Genetics through Meta-Analysis (ENIGMA)11 consortium. Briefly, the CHARGE 1267 
consortium is a collaboration of predominantly population-based cohort studies that investigate the 1268 
genetic and molecular underpinnings of age-related complex diseases, including those of the brain. 1269 
The ENIGMA consortium brings together numerous studies, mainly with a case-control design, which 1270 
performed neuroimaging in a range of neuropsychiatric or neurodegenerative diseases, as well as 1271 
healthy normative populations. Studies participated in either the discovery cohort of European 1272 
ancestry, the replication in European ancestry, or the generalization to other ethnicities. An overview 1273 
of the demographics and type of contribution for each cohort is provided in Supplementary Table 1274 
S1. Written informed consent was obtained from all participants. Each study was approved by the 1275 
respective Institutional Review Board or Local Ethics Committee. 1276 
Genetics 1277 
Genotyping was performed using a variety of commercial arrays across the contributing sites. Both 1278 
samples as well as variants underwent similar quality control procedures based on genetic 1279 
homogeneity, call rate (less than 95%), minor allele frequency (MAF < 0.01), and Hardy-Weinberg 1280 
Equilibrium (HWE p-value less than 1 x 10-6). Good quality variants were used as input for 1281 
imputation to the 1000 Genomes reference panel (phase 1, version 3) using validated software 1282 
packages (MaCH/minimac, IMPUTE2, BEAGLE, GenABLE). Variants that were poorly imputed (R2 1283 
< 0.5) or uncommon (MAF < 0.5%) were removed prior to meta-analysis. Full details on the site-1284 
specific genotyping and quality control may be found in Supplementary Table S2.  1285 
Imaging 1286 
Magnetic resonance imaging (MRI) was obtained from scanners with a diversity of manufacturers, 1287 
field strengths, and acquisition protocols. Images were used to estimate milliliters of intracranial 1288 
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volume from automated segmentations generated by freely available or in-house methods that have 1289 
been described and validated earlier. Most sites measured intracranial volume for each participant by 1290 
multiplying the inverse of the determinant of the transformation matrix required to register the 1291 
subject’s MRI scan to a common template by the template volume (1,948,105 mm3), using the 1292 
FreeSurfer software. Visual inspections were performed to identify and remove poorly segmented 1293 
images. Either all scans were visually inspected, or sites generated histogram plots to identify any 1294 
outliers, which were defined as individuals with a volume more than three standard deviations away 1295 
from the mean. Statistical outliers were only excluded if the segmentations were deemed improper. . 1296 
More site-specific information related to the imaging is available in Supplementary Table S3.  1297 
Genome-wide association studies 1298 
Genome-wide association studies of intracranial volume were performed for each site separately, 1299 
controlling for age, sex, and, when applicable, age2, population stratification variables (MDS / 1300 
principal components), study site (for multi-site studies only), diagnosis (for case-control studies 1301 
only). Studies of unrelated individuals performed a linear regression analyses whereas studies of 1302 
related individuals (ASPSFam, BrainSCALE, ERF, GeneSTAR, GOBS, NeuroIMAGE, NTR-Adults, 1303 
OATS, QTIM, SYS) used linear mixed models to account for familial relationships. Summary 1304 
statistics, including the effect estimates of the genetic variant with intracranial volume under an 1305 
additive model, were exchanged to perform a fixed-effects meta-analysis weighting for sample size in 1306 
METAL40. After the final meta-analysis, variants were excluded if they were only available for fewer 1307 
than 5,000 individuals.  Meta-analyses were stratified by race and done separately for discovery, 1308 
replication, and generalization samples. Beta coefficients were recalculated from Z-scores, allele 1309 
frequencies, and the sample, as described earlier41  Site-specific quantile-quantile plots were generated 1310 
to inspect the presence of genomic inflation. The variance explained by all variants in the GWAS was 1311 
estimated using LD score regression12,42. Sensitivity analyses were performed by excluding patients. 1312 
Functional annotation 1313 
All tracks of the regional association plots were taken from the UCSC Genome Browser Human hg19 1314 
assembly. SNPs (top 5%) shows the top 5% associated variants within the locus and are colored by 1315 
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their correlation to the top variant. Genes shows the gene models from GENCODE version 19. The 1316 
tracks give the predicted chromatin states based on computational integration of ChIP-seq data for 12 1317 
chromatin marks in various human tissues derived from the Roadmap Epigenomics Consortium43. 1318 
Additionally, we used HaploReg version 3 for annotation of the top variants and all variants in LD (> 1319 
0.80) (http://www.broadinstitute.org/mammals/haploreg/haploreg_v3.php).  1320 
Genetic correlation 1321 
The genetic correlation analyses were also performed using LD score regression. The GWAS meta-1322 
analysis of intracranial volume, as well as the height adjusted and height subset meta-analyses, were 1323 
correlated with published GWAS  of the following traits: Child head circumference26, birth weight44, 1324 
birth length45, adult height13, childhood cognitive function46, adult cognitive function47, Alzheimer’s 1325 
disease48, Parkinson’s disease49, white matter lesions50, psychiatric disorders51,  neuroticism52, and 1326 
extraversion53. 1327 
Enrichment analyses 1328 
To determine whether the intracranial volume association results were enriched for certain types of 1329 
genetic variants, we employed two strategies: partitioned heritability and pathway analyses.  1330 
Partitioned heritability was calculated using a previously described method42. This was done by 1331 
partitioning variants by chromosome and by 28 functional classes: coding, UTR, promoter, intron, 1332 
histone marks H3K4me1, H3K4me3, H3K9ac5 and two versions of H3K27ac, open chromatin DNase 1333 
I hypersensitivity Site (DHS) regions, combined chromHMM/Segway predictions, regions that are 1334 
conserved in mammals, super-enhancers and active enhancers from the FANTOM5 panel of samples 1335 
(Finucane et al. page 4)42. Multiple testing thresholds were calculated accordingly: Pthresh = 0.05/(22 1336 
chromosomes) = 2.27 x 10-3  for the chromosomes and Pthresh = 0.05/(28 classes) = 1.79 x 10-3 for the 1337 
functional classes. 1338 
Pathway analyses were performed using the KGG2.554 and MAGENTA55 software packages. LD was 1339 
calculated based with the 1000 Genomes Project European samples as a reference (see URLs). 1340 
Variants were considered to be within a gene if they were within 5 kb of the 3’/5’ UTR based on 1341 
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chromosome positions (hg19) coordinates. Gene-based tests were done with the GATES test54 without 1342 
weighting P-values by predicted functional relevance. Pathway analysis was performed using the 1343 
HYST test of association56. A multiple testing threshold accounting for the number of pathways tested 1344 
resulting in a significance threshold of Pthresh = 0.05/(671 pathways) = 7.45 x 10-5.   1345 
Head growth trajectories 1346 
Head growth trajectory analyses were done within the Generation R study, a longitudinal cohort study 1347 
situated in Rotterdam, the Netherlands. For this analysis we included 2,824 children of European 1348 
ancestry followed prenatally until 6 years of age. Head size was measured at the following points: 1349 
prenatally (using echo) during the first, second, and third trimester, and postnatally (measuring head 1350 
circumference) at 0-2 months, 2 months, 3 months, 4 months, 5-10 months, 10-13 months, 13-17 1351 
months, and 5 years of age. We tested whether a polygenic score of the 7 loci, as well as the 7 loci 1352 
themselves separately, were related to head growth  using linear mixed models and included an 1353 
interaction term between time and the genetic score/variant (SAS software). Next, the predicted 1354 
values were calculated for each person and plotted over time, stratified by genotype (0/1/2 risk alleles) 1355 
using the R software package.   1356 
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FIGURES 
Figure 1. Common genetic variants associated with intracranial volume. 
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      Figure 2. Regional association and functional annotation of novel genome-wide significant loci. 
 
 
FIGURES 
Figure 3. Meta-analysis of intracranial volume and child head circumference. 
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Figure 4. Enrichment analyses of common variants associated with intracranial volume. 
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Figure 5. Temporal trends of intracranial volume loci during pre- and postnatal brain development. 
 
 
 
 
 
 
  
a 
b 
